Long term results of clinical studies strongly support grafalon (R) as standard therapy

The 8-year follow-up results of a randomized 3-phase multicenter trial (http://www.chemdrug.com/sell/24/) in adults with hematologic malignancies clearly showed that the results of the grafalon ® group were better, with a 34% survival rate without severe graft-versus-host disease (GVHD) and relapse in the grafalon ® group, and 13% in the non grafalon ® group The survival rate of the grafalon ® group without immunosuppressive therapy was 47%, while that of the non grafalon ® group was 11% Neovii, which supports the long-term safety of grafalon ®, is pleased to announce the long-term results of the multicenter parallel group pilot trials in Europe and Israel This study was conducted in adult patients who received standard graft-versus-host disease prevention (with or without grafalon ® (atlg) (60 mg / kg total dose)) with standard cyclosporine A and methotrexate, who received myeloablative pretreatment prior to unrelated matched donor hematopoietic stem cell transplantation The results, published in the June edition of the lancet haematology, showed that 47% of the atlg group survived without immunosuppressive therapy for eight years, and 11% of the non atlg [1] group survived without immunosuppressive therapy The main researcher of this study, Jurgen, deputy director of Hematology and Oncology Department of medical school and medical center of University of Freiburg (http://www.chemdrug.com/invest/253/), Germany "The significant improvement of the composite end point" no graft-versus-host disease and no recurrence survival rate "clearly shows the effect of ATLG on patients' treatment, and no sustained incidence rate, which is the main goal of allo stem cell transplantation Most of the patients who receive ATLG graft-versus-host disease after survival are not required to receive immunosuppressive therapy, Professor Finke said Support " Professor Finke is also chairman of the German stem cell transplant working group He added: "the results clearly show the importance of atlg for unrelated matched stem cell transplantation and will have an impact on long-term decision-making and patient consultation (http://www.chemdrug.com/)." Alexandre sudarskis, CEO of neovi, commented: "these breakthrough results undoubtedly demonstrate the long-term effect of grafalon ® (part of the myeloablative pretreatment inhibition program)." He added: "neovi strives to better meet the needs of patients and improve the quality of life through high-performance antibody therapy, so that doctors can use safe and efficient therapy." Neovii supports research and development activities in the fields of stem cell transplantation, solid organ transplantation, immune diseases and blood tumors